SUPPLEMENTARY DATA

Supplementary Table S1. Insulin Titration Algorithms

Basal Insulin	
Mean pre-breakfast blood glucose*	**Adjustment in basal insulin dose**
<3.1 mmol/L (<56 mg/dL)†	–4 IU (if dose >45 IU, reduce by 10%)
3.1 to 4.3 mmol/L (56 to 79 mg/dL)†	–2 IU (if dose >45 IU, reduce by 5%)
4.4 to <6.7 mmol/L (80 to <120 mg/dL)	0
6.7 to 9.9 mmol/L (120 to 179 mg/dL)	+2 IU to 4 IU
10.0 to 14.9 mmol/L (180 to 269 mg/dL)	+4 IU to 6 IU
≥15.0 mmol/L (≥270 mg/dL)	+6 IU to 8 IU and call study site
Bolus Insulin	
Mean mealtime/bedtime blood glucose*	**Change in basal insulin dose**
4.4 to <6.7 mmol/L (80 to <120 mg/dL)	0
6.7 to 8.8 mmol/L (120 to 159 mg/dL)	+1 IU to 2 IU
8.9 to 11.0 mmol/L (160 to 199 mg/dL)	+2 IU to 4 IU
11.1 to 14.9 mmol/L (≥200 to 269 mg/dL)	+4 IU to 6 IU
≥15.0 mmol/L (≥270 mg/dL)	+6 IU to 8 IU and call study site

*Mean of 2 consecutive measurements.

†Unless there is an obvious explanation for the low value, such as a missed meal.

©2015 American Diabetes Association. Published online at http://care.diabetesjournals.org/lookup/suppl/doi:10.2337/dc15-1730/-/DC1

SUPPLEMENTARY DATA

Supplementary Table S2. Sensitivity Analysis: Proportion of Patients with HbA1c reduction ≥0.4% (≥4.4 mmol/mol) and Change in Body Weight <1.0 kg From Baseline at Week 18

	Placebo (n = 117)	**Canagliflozin 100 mg (n = 117)**	**Canagliflozin 300 mg (n = 117)**
n	110	111	111
HbA1c reduction ≥0.4% (≥4.4 mmol/mol) and change in body weight <1.0 kg, n (%)	19 (17.3)	44 (39.6)	48 (43.2)
OR versus placebo		3.36	3.58
HbA1c reduction ≥0.4% (≥4.4 mmol/mol), n (%)	25 (22.7)	50 (45.0)	48 (43.2)
Change in body weight <1.0 kg, n (%)	71 (64.5)	99 (89.2)	111 (100.0)

OR, odds ratio.

©2015 American Diabetes Association. Published online at http://care.diabetesjournals.org/lookup/suppl/doi:10.2337/dc15-1730/-/DC1

SUPPLEMENTARY DATA

Supplementary Figure S1. Study flow diagram.



AE, adverse event; mITT, modified intent-to-treat.

©2015 American Diabetes Association. Published online at http://care.diabetesjournals.org/lookup/suppl/doi:10.2337/dc15-1730/-/DC1